bcl-2 antisense oligonucleotide
Nucleic acidexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2005 (NCT00543231)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Hodgkin Disease · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Lymphoma, T-Cell · Phase 1
- Neoplasms · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bcl-2 antisense oligonucleotide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04072458 | Phase 1 | Nov 30, 2019 | Bio-Path Holdings, Inc. |
| NCT00543231 | Phase 1 | Dec 1, 2005 | Genta |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bio-Path Holdings, Inc. | For profit | 1 | 1 | 1 | 2019 |
| Genta | For profit | 1 | 1 | 1 | 2005 |
2 organizations
Page 1 / 1